Singapur - angielski - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - antihemophilic factor (recombinant) sucrose formulated - injection, powder, lyophilized, for solution - 1000 iu/vial - antihemophilic factor (recombinant) sucrose formulated 1000 iu/vial

Singapur - angielski - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - antihemophilic factor (recombinant) sucrose formulated - injection, powder, lyophilized, for solution - 250iu/vial - antihemophilic factor (recombinant) sucrose formulated 250iu/vial

Singapur - angielski - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - antihemophilic factor (recombinant) sucrose formulated - injection, powder, lyophilized, for solution - 500iu/vial - antihemophilic factor (recombinant) sucrose formulated 500iu/vial

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - permethrin (25:75::cis:trans) - dust - permethrin (25:75::cis:trans) pyrethroid active 10.0 g/kg - insecticide - home - ant | ant mound | european wasp | wasp | wasp nest | argentine ant | pharaoh ant

Arabia Saudyjska - angielski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer healthcare llc, united states - pegylated b domain deleted recombinant human coagulation factor viii damoctocog alfa pegol - powder and solvent for solution for injection - 500 iu

Arabia Saudyjska - angielski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer healthcare llc, united states - pegylated b domain deleted recombinant human coagulation factor viii damoctocog alfa pegol - powder and solvent for solution for injection - 1000 iu

Arabia Saudyjska - angielski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer healthcare llc, united states - pegylated b domain deleted recombinant human coagulation factor viii damoctocog alfa pegol - powder and solvent for solution for injection - 2000 iu

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - coumatetralyl - bait - coumatetralyl coumarin active 0.37 g/kg - vertebrate poison - home - mouse - mus spp. | rat

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin) antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.